Expression of PD-L1, AR, and P53 in urothelial carcinoma and their correlation with clinical prognosis
Objective This study aims to observe the expression of programmed cell death 1 ligand 1 (PD-L1), P53, and androgen receptor (AR) in tumor tissues of patients with urothelial carcinoma (UC) and analyze their correlation with patient prognosis. Methods A retrospective analysis was conducted on 115 UC...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Office of Journal of Diagnostics Concepts & Practice
2025-06-01
|
| Series: | Zhenduanxue lilun yu shijian |
| Subjects: | |
| Online Access: | https://www.qk.sjtu.edu.cn/jdcp/fileup/1671-2870/PDF/1756094091985-350834633.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849222947790651392 |
|---|---|
| author | ZHOU Xiaodie, Qi Rongxin, WANG Xuan, YU Bo, WANG Jianjun, SHI Qunli, RAO Qiu, BAO Wei |
| author_facet | ZHOU Xiaodie, Qi Rongxin, WANG Xuan, YU Bo, WANG Jianjun, SHI Qunli, RAO Qiu, BAO Wei |
| author_sort | ZHOU Xiaodie, Qi Rongxin, WANG Xuan, YU Bo, WANG Jianjun, SHI Qunli, RAO Qiu, BAO Wei |
| collection | DOAJ |
| description | Objective This study aims to observe the expression of programmed cell death 1 ligand 1 (PD-L1), P53, and androgen receptor (AR) in tumor tissues of patients with urothelial carcinoma (UC) and analyze their correlation with patient prognosis. Methods A retrospective analysis was conducted on 115 UC patients with complete clinical data who were admitted consecutively to the General Hospital of Eastern Theater Command and Nanjing Drum Tower Hospital from May 2017 to February 2020. Immunohistochemistry was used to detect the expression of PD-L1, P53, and AR proteins in pathological tissues. The chi-square test (χ² test) was employed to analyze the correlation between these biomarkers and clinicopathological characteristics. Kaplan-Meier survival analysis was used to evaluate the relationship between biomarker expression and prognosis. Results The median follow-up time for the study cohort was 32.5 months (range: 1-54 months). Disease progression occurred in 22 cases, and 17 patients (17.2%) died. The expression rates of PD-L1, P53, and AR in UC tissues were 46.1%, 45.2%, and 7.8%, respectively. Positive PD-L1 expression was associated with clinical progression (54.9% in the positive group vs. 31.8% in the negative group, P=0.016). AR-positive cases were more likely to exhibit multifocal tumor growth (21.7% vs. 4.3%, P=0.019). P53 expression showed no significant correlation with the clinical characteristics of UC. The positive expression of PD-L1, P53, and AR was not associated with overall survival in UC patients. Conclusion Positive PD-L1 expression is associated with disease progression in UC. The expression of PD-L1, P53, and AR is not correlated with short-term survival prognosis in UC patients. Among them, AR expression rate is low and shows no association with short-term prognosis, suggesting that AR-targeted therapy for UC patients has certain limitations. |
| format | Article |
| id | doaj-art-dd40eec151a74edeb0cd92b7fc4f0b5d |
| institution | Kabale University |
| issn | 1671-2870 |
| language | zho |
| publishDate | 2025-06-01 |
| publisher | Editorial Office of Journal of Diagnostics Concepts & Practice |
| record_format | Article |
| series | Zhenduanxue lilun yu shijian |
| spelling | doaj-art-dd40eec151a74edeb0cd92b7fc4f0b5d2025-08-26T01:50:28ZzhoEditorial Office of Journal of Diagnostics Concepts & PracticeZhenduanxue lilun yu shijian1671-28702025-06-01240328629210.16150/j.1671-2870.2025.03.007Expression of PD-L1, AR, and P53 in urothelial carcinoma and their correlation with clinical prognosisZHOU Xiaodie, Qi Rongxin, WANG Xuan, YU Bo, WANG Jianjun, SHI Qunli, RAO Qiu, BAO Wei01. Nanjing Jinling Hospital, Nanjing University School of Medicine, a. Department of Pathology, b. Nuclear medicine Nanjing 210002, China;2. Department of Pathology, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing 210008, ChinaObjective This study aims to observe the expression of programmed cell death 1 ligand 1 (PD-L1), P53, and androgen receptor (AR) in tumor tissues of patients with urothelial carcinoma (UC) and analyze their correlation with patient prognosis. Methods A retrospective analysis was conducted on 115 UC patients with complete clinical data who were admitted consecutively to the General Hospital of Eastern Theater Command and Nanjing Drum Tower Hospital from May 2017 to February 2020. Immunohistochemistry was used to detect the expression of PD-L1, P53, and AR proteins in pathological tissues. The chi-square test (χ² test) was employed to analyze the correlation between these biomarkers and clinicopathological characteristics. Kaplan-Meier survival analysis was used to evaluate the relationship between biomarker expression and prognosis. Results The median follow-up time for the study cohort was 32.5 months (range: 1-54 months). Disease progression occurred in 22 cases, and 17 patients (17.2%) died. The expression rates of PD-L1, P53, and AR in UC tissues were 46.1%, 45.2%, and 7.8%, respectively. Positive PD-L1 expression was associated with clinical progression (54.9% in the positive group vs. 31.8% in the negative group, P=0.016). AR-positive cases were more likely to exhibit multifocal tumor growth (21.7% vs. 4.3%, P=0.019). P53 expression showed no significant correlation with the clinical characteristics of UC. The positive expression of PD-L1, P53, and AR was not associated with overall survival in UC patients. Conclusion Positive PD-L1 expression is associated with disease progression in UC. The expression of PD-L1, P53, and AR is not correlated with short-term survival prognosis in UC patients. Among them, AR expression rate is low and shows no association with short-term prognosis, suggesting that AR-targeted therapy for UC patients has certain limitations.https://www.qk.sjtu.edu.cn/jdcp/fileup/1671-2870/PDF/1756094091985-350834633.pdf|urothelial carcinoma|clinicopathology|programmed cell death 1 ligand 1|androgen receptor|prognosis |
| spellingShingle | ZHOU Xiaodie, Qi Rongxin, WANG Xuan, YU Bo, WANG Jianjun, SHI Qunli, RAO Qiu, BAO Wei Expression of PD-L1, AR, and P53 in urothelial carcinoma and their correlation with clinical prognosis Zhenduanxue lilun yu shijian |urothelial carcinoma|clinicopathology|programmed cell death 1 ligand 1|androgen receptor|prognosis |
| title | Expression of PD-L1, AR, and P53 in urothelial carcinoma and their correlation with clinical prognosis |
| title_full | Expression of PD-L1, AR, and P53 in urothelial carcinoma and their correlation with clinical prognosis |
| title_fullStr | Expression of PD-L1, AR, and P53 in urothelial carcinoma and their correlation with clinical prognosis |
| title_full_unstemmed | Expression of PD-L1, AR, and P53 in urothelial carcinoma and their correlation with clinical prognosis |
| title_short | Expression of PD-L1, AR, and P53 in urothelial carcinoma and their correlation with clinical prognosis |
| title_sort | expression of pd l1 ar and p53 in urothelial carcinoma and their correlation with clinical prognosis |
| topic | |urothelial carcinoma|clinicopathology|programmed cell death 1 ligand 1|androgen receptor|prognosis |
| url | https://www.qk.sjtu.edu.cn/jdcp/fileup/1671-2870/PDF/1756094091985-350834633.pdf |
| work_keys_str_mv | AT zhouxiaodieqirongxinwangxuanyubowangjianjunshiqunliraoqiubaowei expressionofpdl1arandp53inurothelialcarcinomaandtheircorrelationwithclinicalprognosis |